Synthesis and modification of 2-[8-R1-9-R2-10-R3-3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetic acids aimed at searching effective substances with the antibacterial and antifungal activity
Keywords:synthesis, quinazolines, triazines, antibacterial action, antifungal action
AbstractIn the present paper, 50 new derivatives 2-[8-R1-9-R2-10-R3-3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetic acids have been described. It was shown that alkylation of potassium 8-R1-9-R2-10-R3-3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-thiolates by chloracetic acid, chloracetamide, N-R4-chloracetamides and chloracetonitrile yielded corresponding 2-[8-R1-9-R2-10-R3-3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetic acids, their amides and nitriles. For corresponding acids and nitriles, alternative synthetic approaches were elaborated. Limitations of synthetic approaches aimed to the synthesis of target compounds were also discussed. Thus, it was shown, that amides of derivatives 2-[8-R1-9-R2-10-R3-3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetic acids could not be prepared by amonolysis of corresponding ester as result of low reactivity of mentioned compounds. Also, in was claimed that synthesis of nitriles via dehydration of proper amides with phosphorous-oxychloride in dichlormethane was successful not in all cases. Mentioned fact caused by low yields and problems with isolation of target compound from reaction mixture. The structures of synthesized compounds were determined by 1H, 13C NMR, LC–MS analysis. Synthesized compounds were tested for antimicrobial and antifungal activity using standard test cultures: Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and Candida albicans ATCC 885-653. It was shown, that synthesized compounds exhibit high antimicrobial activity against St. aureus (compounds 3.3-3.6, 4.3-4.6, 4.7, 4.8, 4.13-4.16; MIC 12,5-25 µg/ml) and C. albicans (compounds 4.13, 4.14; MIC 12,5 µg/ml). The “structure-activity” relationships were discussed.
Antipenko L.N., Karpenko A.V., Kovalenko S.I. et al. // Arch Pharm. – 2009. – Vol. 342, Iss. 11. – P. 651- 662.
Antipenko L., Karpenko A., Kovalenko S. et al. // Chem. Pharm. Bull. (Tokyo). – 2009. – Vol. 57, №6. – P. 580-585.
Available from: http://www.drugbank.ca/structures/search/.
Baruah B., Dasu K., Vaitilingam B. et al. // Biorg. Med. Chem. - 2004. - Vol. 12, Iss. 9. - P. 1991-1994.
Bedi P.M.S., Kumar V., Mahajan M.P. // Bioorg. Med. Chem. Lett. - 2004. - Vol. 14, Iss. 20. - P. 5211-5213.
Berest G.G., Kovalenko S.I., Nosulenko I.S. et al. // Sci Pharm. - 2012. - Vol. 80, Iss. 1. - P. 37–65.
Berest G.G., Kovalenko S.I., Sinyak R.S. et al. // Journal of Organic and Pharmaceutical Chemistry. - 2010. - №8. - P. 42-52.
Berest G.G., Voskoboynik O.Y., Kovalenko S.I. et al. // Eur. J. Med. Chem. - 2011. - Vol. 46, Iss. 12. - P. 6066-6074.
Institute CaLS. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard.
Jantová S., Ovádeková R., Letašiová S. et al. // Folia Microbiol (Praha). - 2005. - Vol. 50, Iss. 2. - P. 90-94.
Kovalenko S., Nosulenko I., Voskoboynik A. et al. // Med. Chem. Res. - 2013. - Vol. 22, Iss. 6. - P. 2610-2632.
Kovalenko S.I., Voskoboynik A.Yu., Berest G.G. et al. // Sci Pharm. - 2012. - Vol. 80, Iss. 4. - P. 837–865.
Kuarm B.S., Reddy Y.T., Madhav J.V. et al. // Bioorg. Med. Chem. Lett. - 2011. - Vol. 21, Iss. 1. - P. 524-527.
Lamazzi C., Léonce S., Pfeiffer B. et al. // Bioorg. Med. Chem. Lett. - 2000. - Vol. 10, Iss. 19. - P. 2183-2185.
Nasr M.N., Gineinah M.M., El-Bendary E.R. // Arch Pharm. - 2003. - Vol. 336, Iss. 12. - P. 560-566.
Ovadekova R .J.S., Theiszova M., Labuda // J. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. - 2005. - Vol. 149, Iss. 2. - P. 455-459.
Rohini R., Muralidhar Reddy P., Shanker K. et al. // Eur. J. Med. Chem. - 2010. - Vol. 45, Iss. 3. - P. 1200-1205.
Rohini R., Shanker K., Reddy P.M. et al. // Eur. J. Med. Chem. - 2009. - Vol. 44, Iss. 8. - P. 3330-3339.
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).